A Study of IBI362 in Participants With Type 2 Diabetes

Summary

This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects With Type 2 Diabetes.

Timeline

Start

2023-01-06

Primary completion

2024-01-26

Completion

2024-04-09

Outcome

Met primary endpoint

paper Both doses of mazdutide showed non-inferiority and superiority to the 1.5-mg dose of dulaglutide PMID 41407860 ↗

paper with a least-squares mean treatment difference of -0.24% (P = 0.0032) for 4 mg mazdutide PMID 41407860 ↗

release “The results of another Phase 3 study DREAMS-2, involving patients with T2D inadequately controlled by oral antidiabetic drugs (OADs), met the study endpoints” innoventbio.com ↗

release “The primary endpoint was successfully met, showing a robust glucose-lowering efficacy of mazdutide” innoventbio.com ↗

release “Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints” innoventbio.com ↗

release “DREAMS-2 has previously met the study endpoints” innoventbio.com ↗

Publications

• Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, Zhang L, Jin P, Wang X, Cheng Z, Zhang S, Geng J, Guo Y, Hu H, Ma Q, Li L, Du H, Han-Zhang H, Xue F, Deng H, Qian L, Yang W; DREAMS-2 investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026 Apr;652(8108):181-188. doi: 10.1038/s41586-025-10031-z. Epub 2025 Dec 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dulaglutide	Peptide	1.5 mg	Subcutaneous
Subject	Mazdutide	Protein / enzyme biologic	4 mg	Subcutaneous
Subject	Mazdutide	Protein / enzyme biologic	6 mg	Subcutaneous

Indications